These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36176817)

  • 21. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
    Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
    Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Potential of Salivary Lipid-Based Cannabis-Responsive Biomarkers to Evaluate Medical Cannabis Treatment in Children with Autism Spectrum Disorder.
    Siani-Rose M; McKee R; Cox S; Goldstein B; Abrams D; Taylor M; Kurek I
    Cannabis Cannabinoid Res; 2023 Aug; 8(4):642-656. PubMed ID: 35343818
    [No Abstract]   [Full Text] [Related]  

  • 23. Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review.
    Stanciu CN; Brunette MF; Teja N; Budney AJ
    Psychiatr Serv; 2021 Apr; 72(4):429-436. PubMed ID: 33530732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic Use of Δ9-THC and Cannabidiol: Evaluation of a New Extraction Procedure for the Preparation of Cannabis-based Olive Oil.
    Morini L; Porro G; Liso M; Groppi A
    Curr Pharm Biotechnol; 2017; 18(10):828-833. PubMed ID: 29189144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study.
    Sainz-Cort A; Jimenez-Garrido D; Muñoz-Marron E; Viejo-Sobera R; Heeroma J; Bouso JC
    J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):561-570. PubMed ID: 34412109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Behavioral aspects and neurobiological properties underlying medical cannabis treatment in Shank3 mouse model of autism spectrum disorder.
    Poleg S; Kourieh E; Ruban A; Shapira G; Shomron N; Barak B; Offen D
    Transl Psychiatry; 2021 Oct; 11(1):524. PubMed ID: 34645786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The therapeutic role of Cannabidiol in mental health: a systematic review.
    Khan R; Naveed S; Mian N; Fida A; Raafey MA; Aedma KK
    J Cannabis Res; 2020 Jan; 2(1):2. PubMed ID: 33526132
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: Implications for patients and practitioners.
    Miller OS; Elder EJ; Jones KJ; Gidal BE
    Epilepsy Behav; 2022 Feb; 127():108514. PubMed ID: 34998268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems-A Retrospective Feasibility Study.
    Aran A; Cassuto H; Lubotzky A; Wattad N; Hazan E
    J Autism Dev Disord; 2019 Mar; 49(3):1284-1288. PubMed ID: 30382443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Yellow Oil in Healthy Participants.
    Peters EN; Mosesova I; MacNair L; Vandrey R; Land MH; Ware MA; Turcotte C; Bonn-Miller MO
    J Anal Toxicol; 2022 Apr; 46(4):393-407. PubMed ID: 33710277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Δ9-Tetrahydrocannabinol and Cannabidiol Time Courses in the Sera of "Light Cannabis" Smokers: Discriminating Light Cannabis Use from Illegal and Medical Cannabis Use.
    Pichini S; Mannocchi G; Berretta P; Zaami S; Pirani F; Pacifici R; Busardò FP
    Ther Drug Monit; 2020 Feb; 42(1):151-156. PubMed ID: 31389860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antinociceptive and Immune Effects of Delta-9-Tetrahydrocannabinol or Cannabidiol in Male Versus Female Rats with Persistent Inflammatory Pain.
    Britch SC; Goodman AG; Wiley JL; Pondelick AM; Craft RM
    J Pharmacol Exp Ther; 2020 Jun; 373(3):416-428. PubMed ID: 32179573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.
    Arkell TR; Lintzeris N; Kevin RC; Ramaekers JG; Vandrey R; Irwin C; Haber PS; McGregor IS
    Psychopharmacology (Berl); 2019 Sep; 236(9):2713-2724. PubMed ID: 31044290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ
    Boggs DL; Nguyen JD; Morgenson D; Taffe MA; Ranganathan M
    Neuropsychopharmacology; 2018 Jan; 43(1):142-154. PubMed ID: 28875990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis.
    Freeman TP; Craft S; Wilson J; Stylianou S; ElSohly M; Di Forti M; Lynskey MT
    Addiction; 2021 May; 116(5):1000-1010. PubMed ID: 33160291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being.
    Morgan CJ; Gardener C; Schafer G; Swan S; Demarchi C; Freeman TP; Warrington P; Rupasinghe I; Ramoutar A; Tan N; Wingham G; Lewis S; Curran HV
    Psychol Med; 2012 Feb; 42(2):391-400. PubMed ID: 21798112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cannabinoids in the Treatment of Selected Mental Illnesses: Practical Approach and Overview of the Literature.
    Müller-Vahl KR
    Pharmacopsychiatry; 2024 May; 57(3):104-114. PubMed ID: 38428836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neural correlates of interactions between cannabidiol and Δ(9) -tetrahydrocannabinol in mice: implications for medical cannabis.
    Todd SM; Arnold JC
    Br J Pharmacol; 2016 Jan; 173(1):53-65. PubMed ID: 26377899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities.
    Barchel D; Stolar O; De-Haan T; Ziv-Baran T; Saban N; Fuchs DO; Koren G; Berkovitch M
    Front Pharmacol; 2018; 9():1521. PubMed ID: 30687090
    [No Abstract]   [Full Text] [Related]  

  • 40. Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: A human laboratory study.
    Kayser RR; Haney M; Raskin M; Arout C; Simpson HB
    Depress Anxiety; 2020 Aug; 37(8):801-811. PubMed ID: 32383271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.